Evotec has filed a patent for recombinant expression vectors combining mCMV enhancer and huCMV intron A sequences for inducible protein expression. The vectors include PiggyBac ITRs for genomic integration and a method for selecting stable production cell lines. Mammalian host cells are also disclosed for protein production. GlobalData’s report on Evotec gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Evotec SE - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Evotec, NSAID cancer drugs was a key innovation area identified from patents. Evotec's grant share as of January 2024 was 39%. Grant share is based on the ratio of number of grants to total number of patents.

Recombinant expression vector for protein production in mammalian cells

Source: United States Patent and Trademark Office (USPTO). Credit: Evotec SE

A recently filed patent (Publication Number: US20240035037A1) discloses a recombinant expression vector designed for efficient protein production in mammalian host cells. The vector comprises multiple components, including PiggyBac ITR sequences, expression cassettes with control sequences containing mCMV enhancer elements and CMV promoters, open reading frames encoding proteins of interest, polyadenylation sites, and selectable markers. The vector also includes a third expression cassette with an optional inducible promoter and a second protein of interest. The use of a weak constitutive promoter, such as a deleted SV40 promoter, and specific selectable markers like glutamine synthetase are highlighted in the claims.

Furthermore, the patent describes the application of the recombinant expression vector in cultured mammalian host cells, particularly CHO cells. The method outlined involves culturing the host cells in an aqueous medium under physiological conditions to express the protein of interest and subsequently recovering the protein from the medium. Notably, the vector's design allows for the incorporation of TetO sequences in the control sequences, enabling regulation of protein expression through the presence of tetracycline or its analogs in the culture medium. This derepression mechanism ensures controlled and efficient protein production in the host cells, enhancing the utility of the vector for biotechnological applications.

To know more about GlobalData’s detailed insights on Evotec, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies